Page 1

Catalent , Inc. Reports Third Quarter Fiscal 2021 Results investor.catalent.com/financial-news/news-details/2021/Catalent-Inc.-Reports-Third-Quarter-Fiscal-2021 Results / default.aspx 05/04/2021 Catalent , Inc. ( NYSE : CTLT ) , the leading global provider of advanced delivery technologies , development , and manufacturing solutions for drugs , biologics , cell and gene therapies , and consumer health products , today announced financial results for the third quarter of fiscal 2021 , which ended March 31 , 2021 . " I am proud of Catalent's robust third - quarter results and excited by the strong foundation we've built for continued growth , through the dedication and ingenuity of our talented workforce , " said John Chiminski , Chair and Chief Executive Officer of Catalent , Inc. " Throughout the pandemic , we've worked around - the - clock to deliver for patients , while also investing in capabilities and capacity to ensure Catalent can continue to meet global demand for COVID - 19 vaccines and other important customer programs for years to come . " Third Quarter 2021 Consolidated Results Net revenue of $ 1.05 billion increased 38 % as reported , or 35 % in constant currency , from the $ 760.6 million reported for the third quarter a year ago . Overall organic net revenue growth ( i.e. , excluding the effect of acquisitions ) was 35 % . Net earnings were $ 231.8 million , including a $ 184.0 million gain attributable to the sale of the blow - fill - seal business , which closed on March 31 , 2021. After accounting for the net earnings attributable to holders of Catalent's Series A convertible preferred stock , net earnings attributable to common shareholders were $ 217.1 million , or $ 1.27 per basic share , compared to net earnings attributable to common shareholders of $ 11.8 million , or $ 0.08 per basic share , in the third quarter a year ago . EBITDA from operations ( 1 ) was $ 419.9 million , an increase of $ 291.0 million from $ 128.9 million in the third quarter a year ago . Third quarter fiscal 2021 Adjusted EBITDA ( 1 ) was $ 274.2 million , or 26.0 % of net revenue , compared to $ 185.4 million , or 24.4 % of net revenue , in the third quarter a year ago . This represents an increase of 48 % as reported , and an increase of 44 % on a constant - currency basis . Adjusted Net Income ( 1 ) was $ 148.3 million , or $ 0.82 per diluted share , compared to Adjusted Net Income of $ 82.9 million , or $ 0.50 per diluted share , in the third quarter a year ago . Third Quarter 2021 Segment Review Biologics 1/25